{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:35:16Z","timestamp":1736919316122,"version":"3.33.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00120-024-02478-1","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T21:11:50Z","timestamp":1732828310000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fr\u00fcherkennung beim Prostatakarzinom\u00a0\u2013 individualisiert, risikoadaptiert und erfolgreich","Early detection of prostate cancer\u2014individualized, risk-adapted and successful"],"prefix":"10.1007","volume":"64","author":[{"given":"Anne","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bu\u00dfhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jale","family":"Lakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouvier","family":"Al-Monajjed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Philipp","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"2478_CR1","volume-title":"Krebs in Deutschland","author":"Robert Koch Institut","year":"2021","unstructured":"Robert Koch Institut (2021) Krebs in Deutschland"},{"issue":"7","key":"2478_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJ Bell","year":"2015","unstructured":"Bell\u00a0KJ, Del Mar\u00a0C, Wright\u00a0G, Dickinson\u00a0J, Glasziou\u00a0P (2015) Prevalence of incidental prostate cancer: A\u00a0systematic review of autopsy studies. Int J Cancer 137(7):1749\u20131757","journal-title":"Int J Cancer"},{"key":"2478_CR3","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic\u00a0D, Djulbegovic\u00a0M, Jung\u00a0JH, Hwang\u00a0EC, Zhou\u00a0Q, Cleves\u00a0A et\u00a0al (2018) Prostate cancer screening with prostate-specific antigen (PSA) test: a\u00a0systematic review and meta-analysis. BMJ 362:k3519","journal-title":"BMJ"},{"issue":"22","key":"2478_CR4","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1001\/jama.2024.5814","volume":"331","author":"X Feng","year":"2024","unstructured":"Feng\u00a0X, Zahed\u00a0H, Onwuka\u00a0J, Callister\u00a0MEJ, Johansson\u00a0M, Etzioni\u00a0R et\u00a0al (2024) Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A\u00a0Systematic Review and Meta-Analysis. JAMA 331(22):1910\u20131917","journal-title":"JAMA"},{"issue":"13","key":"2478_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der\u00a0FH, Hugosson\u00a0J, Roobol\u00a0MJ, Tammela\u00a0TL, Ciatto\u00a0S, Nelen\u00a0V et\u00a0al (2009) Screening and prostate-cancer mortality in a\u00a0randomized European study. N\u00a0Engl J Med 360(13):1320\u20131328","journal-title":"N Engl J Med"},{"issue":"1","key":"2478_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson\u00a0J, Roobol\u00a0MJ, M\u00e5nsson\u00a0M, Tammela\u00a0TLJ, Zappa\u00a0M, Nelen\u00a0V et\u00a0al (2019) A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 76(1):43\u201351","journal-title":"Eur Urol"},{"issue":"4","key":"2478_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","volume":"84","author":"V de II","year":"2023","unstructured":"de\u00a0V II, Meertens\u00a0A, Hogenhout\u00a0R, Remmers\u00a0S, Roobol\u00a0MJ (2023) A\u00a0Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol 84(4):426\u2013434","journal-title":"Eur Urol"},{"issue":"3","key":"2478_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","volume":"68","author":"R Arnsrud Godtman","year":"2015","unstructured":"Arnsrud Godtman\u00a0R, Holmberg\u00a0E, Lilja\u00a0H, Stranne\u00a0J, Hugosson\u00a0J (2015) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18\u00a0years in the G\u00f6teborg randomized population-based prostate cancer screening trial. Eur Urol 68(3):354\u2013360","journal-title":"Eur Urol"},{"issue":"1","key":"2478_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","volume":"52","author":"J Hugosson","year":"2018","unstructured":"Hugosson\u00a0J, Godtman\u00a0RA, Carlsson\u00a0SV, Aus\u00a0G, Grenabo Bergdahl\u00a0A, Lodding\u00a0P et\u00a0al (2018) Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52(1):27\u201337","journal-title":"Scand J Urol"},{"issue":"1","key":"2478_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","volume":"71","author":"S Carlsson","year":"2017","unstructured":"Carlsson\u00a0S, Assel\u00a0M, Ulmert\u00a0D, Gerdtsson\u00a0A, Hugosson\u00a0J, Vickers\u00a0A et\u00a0al (2017) Screening for Prostate Cancer Starting at Age 50\u201354 Years. A\u00a0Population-based Cohort Study. Eur Urol 71(1):46\u201352","journal-title":"Eur Urol"},{"issue":"17","key":"2478_CR11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2024.4011","volume":"331","author":"RM Martin","year":"2024","unstructured":"Martin\u00a0RM, Turner\u00a0EL, Young\u00a0GJ, Metcalfe\u00a0C, Walsh\u00a0EI, Lane\u00a0JA et\u00a0al (2024) Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A\u00a0Secondary Analysis of the CAP Randomized Clinical Trial. JAMA 331(17):1460\u20131470","journal-title":"JAMA"},{"key":"2478_CR12","unstructured":"Konsultationsfassung S3-Leitlinie Prostatakarzinom. Leitlinienprogramm Onkologie 2024."},{"key":"2478_CR13","doi-asserted-by":"crossref","unstructured":"Beyer K, Leenen R, Venderbos LDF, Helleman J, Denijs F, Bramer W et\u00a0al (2024) Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE\u2011U Consortium. J\u00a0Pers Med 14(1)","DOI":"10.3390\/jpm14010084"},{"key":"2478_CR14","unstructured":"Tillmanns H, Schillinger G, Dr\u00e4hter H (2022) Inanspruchnahme von Fr\u00fcherkennungsleistungen der gesetzlichen Krankenversicherung durch AOK-Versicherte im Erwachsenenalter. Beitrag Des Wissentschaftlichen Instituts Aok"},{"issue":"2","key":"2478_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"L Naji","year":"2018","unstructured":"Naji\u00a0L, Randhawa\u00a0H, Sohani\u00a0Z, Dennis\u00a0B, Lautenbach\u00a0D, Kavanagh\u00a0O et\u00a0al (2018) Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A\u00a0Systematic Review and Meta-Analysis. Ann Fam Med 16(2):149\u2013154","journal-title":"Ann Fam Med"},{"issue":"6","key":"2478_CR16","first-page":"566","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute\u00a0A, Becker\u00a0N, Lakes\u00a0J, Radtke\u00a0JP, Kuczyk\u00a0M, Peters\u00a0I et\u00a0al (2023) Digital Rectal Examination Is Not a\u00a0Useful Screening Test for Prostate Cancer. Eur Urol 6(6):566\u2013573","journal-title":"Eur Urol"},{"issue":"2","key":"2478_CR17","first-page":"105","volume":"85","author":"M Boschheidgen","year":"2024","unstructured":"Boschheidgen\u00a0M, Albers\u00a0P, Schlemmer\u00a0HP, Hellms\u00a0S, Bonekamp\u00a0D, Sauter\u00a0A et\u00a0al (2024) Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 85(2):105\u2013111","journal-title":"Eur Urol"},{"issue":"2","key":"2478_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/caac.20066","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf\u00a0AM, Wender\u00a0RC, Etzioni\u00a0RB, Thompson\u00a0IM, D\u2019Amico\u00a0AV, Volk\u00a0RJ et\u00a0al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60(2):70\u201398","journal-title":"CA Cancer J Clin"},{"issue":"9959","key":"2478_CR19","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der\u00a0FH, Hugosson\u00a0J, Roobol\u00a0MJ, Tammela\u00a0TL, Zappa\u00a0M, Nelen\u00a0V et\u00a0al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13\u00a0years of follow-up. Lancet 384(9959):2027\u20132035","journal-title":"Lancet"},{"key":"2478_CR20","doi-asserted-by":"publisher","first-page":"e071082","DOI":"10.1136\/bmj-2022-071082","volume":"381","author":"A Vickers","year":"2023","unstructured":"Vickers\u00a0A, O\u2019Brien\u00a0F, Montorsi\u00a0F, Galvin\u00a0D, Bratt\u00a0O, Carlsson\u00a0S et\u00a0al (2023) Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ 381:e71082","journal-title":"BMJ"},{"key":"2478_CR21","volume-title":"EAU Annual Congress Milan 2023","author":"EAU Guidelines","year":"2023","unstructured":"Guidelines\u00a0EAU (2023) EAU Annual Congress Milan 2023"},{"issue":"11","key":"2478_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C, Albers\u00a0P, Herkommer\u00a0K, Gschwend\u00a0J, Imkamp\u00a0F, Peters\u00a0I et\u00a0al (2022) A\u00a0randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer 150(11):1861\u20131869","journal-title":"Int J Cancer"},{"key":"2478_CR23","doi-asserted-by":"crossref","unstructured":"Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, Lakes J, Radtke JP et\u00a0al (2024) Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Eur Urol","DOI":"10.1016\/j.eururo.2024.04.030"},{"issue":"3","key":"2478_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.eururo.2020.12.010","volume":"79","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel\u00a0H, Hogenhout\u00a0R, Albers\u00a0P, van den Bergh\u00a0RCN, Barentsz\u00a0JO, Roobol\u00a0MJ (2021) Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 79(3):327\u2013329","journal-title":"Eur Urol"},{"key":"2478_CR25","volume-title":"S3-Leitlinie Prostatakarzinom","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):","year":"2021","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): (2021) S3-Leitlinie Prostatakarzinom Bd. 6.2"},{"issue":"9","key":"2478_CR26","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m\u00a0T, Discacciati\u00a0A, Bergman\u00a0M, Clements\u00a0M, Aly\u00a0M, Annerstedt\u00a0M et\u00a0al (2021) Prostate cancer screening using a\u00a0combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a\u00a0prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol 22(9):1240\u20131249","journal-title":"Lancet Oncol"},{"issue":"2","key":"2478_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","volume":"55","author":"K Kohestani","year":"2021","unstructured":"Kohestani\u00a0K, M\u00e5nsson\u00a0M, Arnsrud Godtman\u00a0R, Stranne\u00a0J, Wallstr\u00f6m\u00a0J, Carlsson\u00a0S et\u00a0al (2021) The G\u00d6TEBORG prostate cancer screening 2\u00a0trial: a\u00a0prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol 55(2):116\u2013124","journal-title":"Scand J Urol"},{"issue":"3","key":"2478_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey\u00a0B, Rosenkrantz\u00a0AB, Haider\u00a0MA, Padhani\u00a0AR, Villeirs\u00a0G, Macura\u00a0KJ et\u00a0al (2019) Prostate Imaging Reporting and Data System Version\u00a02.1: 2019 Update of Prostate Imaging Reporting and Data System Version\u00a02. Eur Urol 76(3):340\u2013351","journal-title":"Eur Urol"},{"issue":"1","key":"2478_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/JU.0000000000000757","volume":"204","author":"MA Pagniez","year":"2020","unstructured":"Pagniez\u00a0MA, Kasivisvanathan\u00a0V, Puech\u00a0P, Drumez\u00a0E, Villers\u00a0A, Olivier\u00a0J (2020) Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Urol 204(1):24\u201332","journal-title":"J Urol"},{"issue":"7","key":"2478_CR30","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00261-023-03929-7","volume":"48","author":"R Nicola","year":"2023","unstructured":"Nicola\u00a0R, Bittencourt\u00a0LK (2023) PI-RADS 3\u00a0lesions: a\u00a0critical review and discussion of how to improve management. Abdom Radiol (ny) 48(7):2401\u20132405","journal-title":"Abdom Radiol (ny)"},{"issue":"6","key":"2478_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas\u00a0T, Shim\u00a0SR, Basile\u00a0G, Baboudjian\u00a0M, K\u00f3i\u00a0T, Przydacz\u00a0M et\u00a0al (2024) Magnetic Resonance Imaging in Prostate Cancer Screening: A\u00a0Systematic Review and Meta-Analysis. JAMA Oncol 10(6):745\u2013754","journal-title":"JAMA Oncol"},{"issue":"2","key":"2478_CR32","doi-asserted-by":"publisher","first-page":"e180219","DOI":"10.1001\/jamanetworkopen.2018.0219","volume":"1","author":"L Boesen","year":"2018","unstructured":"Boesen\u00a0L, N\u00f8rgaard\u00a0N, L\u00f8gager\u00a0V, Balslev\u00a0I, Bisbjerg\u00a0R, Thestrup\u00a0KC et\u00a0al (2018) Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. Jama Netw Open 1(2):e180219","journal-title":"Jama Netw Open"},{"issue":"4","key":"2478_CR33","doi-asserted-by":"publisher","first-page":"e070280","DOI":"10.1136\/bmjopen-2022-070280","volume":"13","author":"A Asif","year":"2023","unstructured":"Asif\u00a0A, Nathan\u00a0A, Ng\u00a0A, Khetrapal\u00a0P, Chan\u00a0VW, Giganti\u00a0F et\u00a0al (2023) Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a\u00a0prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol. BMJ Open 13(4):e70280","journal-title":"BMJ Open"},{"issue":"11","key":"2478_CR34","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.1007\/s00330-021-07907-9","volume":"31","author":"J Wallstr\u00f6m","year":"2021","unstructured":"Wallstr\u00f6m\u00a0J, Geterud\u00a0K, Kohestani\u00a0K, Maier\u00a0SE, M\u00e5nsson\u00a0M, Pihl\u00a0CG et\u00a0al (2021) Bi- or multiparametric MRI in a\u00a0sequential screening program for prostate cancer with PSA followed by MRI? Results from the G\u00f6teborg prostate cancer screening 2\u00a0trial. Eur Radiol 31(11):8692\u20138702","journal-title":"Eur Radiol"},{"issue":"3","key":"2478_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt\u00a0O, Godtman\u00a0RA, Jiborn\u00a0T, Wallstr\u00f6m\u00a0J, Akre\u00a0O, Carlsson\u00a0S et\u00a0al (2024) Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol 85(3):207\u2013214","journal-title":"Eur Urol"},{"issue":"19","key":"2478_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Rannikko\u00a0AS, Borghi\u00a0M, Panebianco\u00a0V, Mynderse\u00a0LA, Vaarala\u00a0MH et\u00a0al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N\u00a0Engl J Med 378(19):1767\u20131777","journal-title":"N Engl J Med"},{"issue":"4","key":"2478_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest\u00a0M, Cornel\u00a0E, Isra\u00ebl\u00a0B, Hendriks\u00a0R, Padhani\u00a0AR, Hoogenboom\u00a0M et\u00a0al (2019) Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-na\u00efve Men with Elevated Prostate-specific Antigen: A\u00a0Large Prospective Multicenter Clinical Study. Eur Urol 75(4):570\u2013578","journal-title":"Eur Urol"},{"issue":"1","key":"2478_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re\u00a0O, Puech\u00a0P, Renard-Penna\u00a0R, Claudon\u00a0M, Roy\u00a0C, M\u00e8ge-Lechevallier\u00a0F et\u00a0al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a\u00a0prospective, multicentre, paired diagnostic study. Lancet Oncol 20(1):100\u2013109","journal-title":"Lancet Oncol"},{"issue":"5","key":"2478_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.euf.2016.10.009","volume":"4","author":"M Eklund","year":"2018","unstructured":"Eklund\u00a0M, Nordstr\u00f6m\u00a0T, Aly\u00a0M, Adolfsson\u00a0J, Wiklund\u00a0P, Brandberg\u00a0Y et\u00a0al (2018) The Stockholm\u20113 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50\u201369\u202fyr Compared with Current Prostate Cancer Testing. Eur Urol Focus 4(5):707\u2013710","journal-title":"Eur Urol Focus"},{"issue":"12","key":"2478_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson\u00a0J, Godtman\u00a0RA, Wallstrom\u00a0J, Axcrona\u00a0U, Bergh\u00a0A, Egevad\u00a0L et\u00a0al (2024) Results after Four Years of Screening for Prostate Cancer with PSA and MRI. N\u00a0Engl J Med 391(12):1083\u20131095","journal-title":"N Engl J Med"},{"key":"2478_CR41","doi-asserted-by":"crossref","unstructured":"Josefsson A, M\u00e5nsson M, Kohestani K, Spyratou V, Wallstr\u00f6m J, Hellstr\u00f6m M et\u00a0al (2024) Performance of 4Kscore as a\u00a0Reflex Test to Prostate-specific Antigen in the G\u00d6TEBORG\u20112 Prostate Cancer Screening Trial. Eur Urol","DOI":"10.1016\/j.eururo.2024.04.037"},{"issue":"17","key":"2478_CR42","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen\u00a0A, Tammela\u00a0TLJ, Mirtti\u00a0T, Lilja\u00a0H, Tolonen\u00a0T, Kentt\u00e4mies\u00a0A et\u00a0al (2024) Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA 331(17):1452\u20131459","journal-title":"JAMA"},{"key":"2478_CR43","doi-asserted-by":"crossref","unstructured":"Vigneswaran HT, Eklund M, Discacciati A, Nordstr\u00f6m T, Hubbard RA, Perlis N et\u00a0al Stockholm3 in a\u00a0Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A\u00a0Prospective Multicentered Trial. J\u00a0Clin Oncol 2024:Jco2400152","DOI":"10.1016\/S0302-2838(24)01296-X"},{"key":"2478_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.euros.2024.05.010","volume":"66","author":"OD McLeod","year":"2024","unstructured":"McLeod\u00a0OD, Palsdottir\u00a0T, Walz\u00a0J, Tilki\u00a0D, Briganti\u00a0A, Stabile\u00a0A et\u00a0al (2024) Cost Analysis of Prostate Cancer Care Using a\u00a0Biomarker-enhanced Diagnostic Strategy with Stockholm3. Eur Urol Open Sci 66:26\u201332","journal-title":"Eur Urol Open Sci"},{"issue":"12","key":"2478_CR45","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1634\/theoncologist.2009-0132","volume":"14","author":"A Brandt","year":"2009","unstructured":"Brandt\u00a0A, Bermejo\u00a0JL, Sundquist\u00a0J, Hemminki\u00a0K (2009) Age at diagnosis and age at death in familial prostate cancer. Oncologist 14(12):1209\u20131217","journal-title":"Oncologist"},{"issue":"6","key":"2478_CR46","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page\u00a0EC, Bancroft\u00a0EK, Brook\u00a0MN, Assel\u00a0M, Al Battat\u00a0HM, Thomas\u00a0S et\u00a0al (2019) Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA\u00a02 Mutation Carriers. Eur Urol 76(6):831\u2013842","journal-title":"Eur Urol"},{"issue":"11","key":"2478_CR47","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","volume":"22","author":"EK Bancroft","year":"2021","unstructured":"Bancroft\u00a0EK, Page\u00a0EC, Brook\u00a0MN, Thomas\u00a0S, Taylor\u00a0N, Pope\u00a0J et\u00a0al (2021) A\u00a0prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 22(11):1618\u20131631","journal-title":"Lancet Oncol"},{"key":"2478_CR48","volume-title":"Effect of polygenic risk score for clinically significant prostate cancer in a\u00a0screening program: The BARCODE 1\u00a0study results","author":"A Ros","year":"2024","unstructured":"Ros\u00a0A, Eeles\u00a0EKB, McHugh\u00a0JK, Saunders\u00a0E (2024) Effect of polygenic risk score for clinically significant prostate cancer in a\u00a0screening program: The BARCODE 1\u00a0study results. ASCO Publications"},{"issue":"5","key":"2478_CR49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00120-023-02062-z","volume":"62","author":"AE Handke","year":"2023","unstructured":"Handke\u00a0AE, Albers\u00a0P, Schimm\u00f6ller\u00a0L, Bonekamp\u00a0D, Asbach\u00a0P, Schlemmer\u00a0HP et\u00a0al (2023) Systematic or targeted fusion-guided biopsy. Urologie 62(5):464\u2013472","journal-title":"Urologie"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02478-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:38:54Z","timestamp":1736901534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02478-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2478"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02478-1","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"22 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0H\u00fcbner, I.\u00a0Bu\u00dfhoff, J.\u00a0Lakes, R.\u00a0Al-Monajjed, J.P.\u00a0Radtke und P.\u00a0Albers geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}